J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

New machine learning techniques plumb vast "data lakes" to help researchers design faster, cheaper, more effective clinical ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Alume Biosciences is pleased to announce the appointment of Rick Gonzalez as Chief Commercial Officer. With over three ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of ... The success of clinical trials hinges on ...

Advisory committees/consultant: Abbott, Astra-Zeneca, Bayer, Boehringer I, Dexcom, Eli Lilly, GlaxoSmithKline Inc ... We must bear in mind that their success, both commercial and medical, is also the ...

CHELMSFORD, MA / ACCESSWIRE / September 16, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), a global leader in customer experience for over 100 years, today announced a leadership transition within its sales ...

Lexington ranks in the top 10 among mid-size U.S. cities for attracting Generation Z graduates to live and begin their work ...

The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by GlaxoSmithKline ... jury is out on that. The success of clinical trials ...